TruthArchive.ai - Related Video Feed

Dr. Pretorius and a colleague discuss unusual clotting observed after COVID-19 vaccination, including embalmers reporting back pressure when introducing embalming fluid and the extraction of very long, congealed clots—six inches to several feet—as well as patients with long brachial clots. They note thousands of clotting reports in VAERS across all vaccine types, describing these clots as not normal. Some clots cause major emboli affecting circulation to the lungs, detected by scans and perfusion studies, while others are microclots with a branching pattern visible in imaging. A clinician also shared a photo of a clot with a complete branching pattern into medium and smaller vessels. Dr. Pretorius’ work is cited to explain the mechanism: spike protein can induce immediate clumping of proteins in platelet-poor plasma in the absence of platelets, a highly unusual clotting pathway not relying on the classical coagulation cascade. This is described as a proteinaceous, pseudo-amyloid–like clot. The spike protein is reported to circulate after vaccination, with studies in the Journal of Immunology showing spikes in circulation and exosomes up to four months after shots. Long-haul COVID data (Patterson’s study) reportedly shows S1 protein present in nonclassical monocytes in blood, suggesting persistence of spike protein, whether from infection or the vaccine, which can induce clotting pathways on its own. Dr. Pretorius discusses observations of upregulation of intercellular adhesion molecules (ICAMs) on leukocytes within clots, causing white blood cells to adhere in addition to fibrin, contributing to difficulty in dissolving these clots. Concerning treatment and detection, the speakers describe depletion of plasminogen, reducing the body’s ability to break down clots, and note that standard anticoagulants are less effective against these clots, which are described as amyloid-like and atypical. They emphasize that these are not the classical clotting pathways involving platelet activation and typical thrombin–fibrin cascades. They contrast this with expectations of standard clotting mechanisms and reference the unusual, non-classical pathway highlighted by Pretorius. The discussion also mentions the idea that spike protein in circulation can drive clotting without the usual platelet activation, and that some patients have continued to experience spike-related effects long after vaccination. They assert that vaccines were developed targeting the original Wuhan strain and may not cover Omicron; they suggest the shot’s risk-benefit balance is unfavorable given ongoing clotting, immune suppression, and cancer-inducing pathways, and they claim data indicate those who receive two or three shots may acquire Omicron at a higher rate than those unvaccinated. They conclude that the shot is expired for a virus that is no longer circulating in its original form and argue that vaccination induces dangerous pathologic processes with no protective benefit.

Research conducted by Bruce Patterson at InCelDx reveals that spike proteins can remain in the body for extended periods. In severe COVID cases, the s one segment was found in white blood cells for up to 15 months after infection. Even after vaccination, the full-length spike protein, including the s one and s two segments, was detected in white blood cells for at least 9 months. Another study from Stanford, led by Roelkern and colleagues, discovered messenger RNA, the genetic code for the spike protein, in lymph nodes for up to 2 months. These findings suggest that both messenger RNA and spike proteins can persist in the human body for several months.

Bonjour à tous, Anaïs Bloqué, docteur en biologie santé, explique les impacts de la protéine Spike du SARS-CoV-2 sur le système immunitaire inné, basés sur son article récent. La Spike seule n'active pas complètement le TLR 4, un récepteur immunitaire, et ne permet pas la production d'interférons de type 1, essentiels pour lutter contre le virus. Pour une activation complète, la Spike doit s'associer au LPS (des bactéries gram négatifs). L'activation des interférons 1 augmente l'expression d'ACE2, le récepteur du virus, sensibilisant l'organisme à l'infection. Les interférons 1 peuvent aussi être activés par les RLR, notamment MDA5, qui détecte l'ARN messager modifié des vaccins anti-COVID. De plus, la Spike, protéine amyloïde, peut déclencher le TLR 4 en s'associant aux fibres amyloïdes A bêta 42, créant un "double effet amyloïde". L'augmentation de NF-κB par les interférons 1 peut bloquer la p53, un suppresseur de tumeur, et induire l'expression du MIR-29b, qui bloque ACE2. Chez les personnes avec comorbidités, ayant déjà de faibles niveaux d'ACE2, cette interaction Spike-LPS devient dangereuse, créant une boucle d'amplification inflammatoire. La Spike persiste longtemps dans l'organisme, et avec ses propriétés amyloïdes, pourrait entraîner des pathologies dégénératives à long terme. --- Hello everyone, Anaïs Bloqué, Doctor of Philosophy in Health Biology, explains the impacts of the SARS-CoV-2 Spike protein on the innate immune system, based on her recent article. The Spike alone does not fully activate TLR 4, an immune receptor, and does not allow the production of type 1 interferons, which are essential for fighting the virus. For complete activation, the Spike must associate with LPS (from gram-negative bacteria). Activation of interferon 1 increases the expression of ACE2, the virus's receptor, sensitizing the body to infection. Interferons 1 can also be activated by RLRs, in particular MDA5, which detects the modified messenger RNA of anti-COVID vaccines. In addition, Spike, an amyloid protein, can trigger TLR 4 by associating with amyloid A beta 42 fibers, creating a "double amyloid effect". The increase in NF-κB by interferons 1 can block p53, a tumor suppressor, and induce the expression of MIR-29b, which blocks ACE2. In people with comorbidities, who already have low levels of ACE2, this Spike-LPS interaction becomes dangerous, creating an inflammatory amplification loop. Spike persists in the body for a long time, and with its amyloid properties, could lead to long-term degenerative pathologies.

The discussion centers on evidence linking myocarditis and pericarditis to mRNA vaccination and the proposed mechanism behind it. It references a 2022 German study reporting that endomyocardial biopsy data from people with myocarditis showed cardiac detection of the spike protein and CD4+ T cell–dominated inflammation, suggesting a vaccine-triggered autoimmune reaction. The presenters note headlines at the time comparing myocarditis risk to infection, with claims that infection causes more myocarditis, and remind that vaccines were said not to stop transmission. They then cite a large Israeli population study from the same year involving subjects not vaccinated against SARS-CoV-2, which found no increase in the incidence of myocarditis or pericarditis, implying no observed vaccine-related signal in that cohort. Attention shifts to a more recent study published in Circulation by the American Heart Association, described as a high-impact, non-fringe journal, indicating a clearer mechanism has been demonstrated. The study described used an experimental mouse model to induce cardiac damage and then compared it to human cases with heart damage following vaccination. It states that T cells from patients with acute myocarditis or myopericarditis recognize vaccine-encoded spike epitopes that are homologous to cardiac self proteins, meaning the immune response to the spike protein can cross-react with heart tissues. The researchers further report that functional responses to potassium channels in patients with mild pericarditis after mRNA vaccination, but not in patients with COVID-19, showed an expanded pattern of cytokine production similar to that observed in myopericarditis mice and in autoimmune myocarditis. In plain terms, the summary of their takeaway is that post-mRNA vaccine myopericarditis is driven by molecular mimicry: the immune system cannot distinguish self from non-self, leading to an autoimmune attack on heart tissue in susceptible patients. The distribution of the vaccine (its widespread dissemination) is cited as a factor that makes patients susceptible by promoting heart-homing imprinting, effectively creating an anti-heart autoimmune response. The speakers emphasize that this Circulation article is a top-tier source, underscoring that the mechanism has been demonstrated with both animal models and human pathology, supporting the claim that the phenomenon has a defined immunological basis.

Je suis Anaïs Bloqué, docteur en biologie, expliquant les impacts de la protéine Spike du SARS-CoV-2 sur le système immunitaire. La Spike seule ne déclenche pas la production d'interférons de type 1, nécessitant une association avec le LPS pour activer le TLR4. Cette interaction peut augmenter l'expression d'ACE2, favorisant l'infection virale. Des boucles inflammatoires complexes peuvent se former, menant à des conséquences potentiellement dangereuses, surtout chez les individus avec des comorbidités. La persistance de la protéine Spike dans l'organisme peut entraîner des problèmes dégénératifs à long terme.

To help cleanse the body of spike proteins from both the virus and the vaccine, a combination of nattokinase (2,000 to 4,000 units twice daily), bromelain (500 to 1,000 milligrams once daily), and curcumin (500 to 1,000 milligrams daily) is recommended. The spike protein, an engineered protein, may remain in the body for a long time and can lead to autoimmune responses, where the body attacks itself. Long COVID symptoms are attributed to the presence of this spike protein, which can persist after infection and is more abundant following vaccination. Antibodies against the spike protein can be measured, indicating its lingering presence in the body.

Speaker 0 states that the study confirms suspicions from the past five years that common sense has deteriorated in the population. The study analyzed the VAERS system from the 1990s to 2024 and examined PRRs (proportional reporting ratios), which measure how many more adverse events occur with the COVID shots compared to the flu shot or other vaccines. It reports 8686 safety signals of neuropsychiatric adverse events, with some up to 3,000 times higher than the flu shot. The safety signal threshold defined by CDC/FDA for PRRs is greater than two, and all reported signals exceeded this threshold. The listed conditions include schizophrenia, dementia, Alzheimer's, cognitive impairment, strokes, brain clots, homicidal tendencies, homicidal behavior, and psychosis, described as people hallucinating and brain damage. The speaker notes that this large number of safety signals aligns with a recent study indicating that people who had strokes showed toxic spike protein production in their brains for up to seventeen months after vaccination, which the speaker suggests explains the observed deterioration in cognitive function.

For biodistribution, Pfizer did not use the actual spike mRNA product in their studies. Instead, they substituted in a luciferase reporter mRNA packaged in the same lipid nanoparticles. This approach allowed them to track where the mRNA traveled in rodents. The studies showed that following intramuscular injection, most of the mRNA remained at the site of injection, but there was also notable levels detected in the liver. Despite the limitations of this approach, which can underestimate low level or transient distributions to other tissues, it nevertheless showed that the vaccine components do not remain confined to the injection site. Next slide. For Moderna, no dedicated biodistribution study was performed with the COVID mRNA itself. Instead, data was provided from a surrogate product, a CMV mRNA, mRNA-sixteen 47, which used the same lipid nanoparticle formulation. In their rat study, after intramuscular injections, high levels of the mRNA were detected at the injection site, but also in multiple organs such as the draining lymph nodes, spleen, eye, and liver. Lower levels were also found across a wide range of tissues, including the heart, lungs, testes, and brain. Importantly, this study clearly showed that the mRNA can cross the blood brain barrier. Next slide. Consistent with what is seen in animal studies, the vaccine mRNA and its spike protein have been detected in humans across multiple tissues, including blood, lymph nodes, the heart, and even the brain. These findings make it clear that the mRNA does not remain confined to the injection site. Importantly, persistence has been documented well beyond the initial hours or days, lasting weeks in some tissues, and in certain studies detectable for many months. Next slide. To summarize the biodistribution data, it's important to note that neither Moderna nor Pfizer used their actual commercial mRNA vaccine products in the preclinical biodistribution studies. Instead, they relied on surrogate construct packaged in same or similar lipid nanoparticles. Second, the results of those studies show that the mRNA and lipid nanoparticles were not confined to the injection site. Systemic distribution was observed with evidence that the mRNA can cross the blood brain barrier. Consistent with these findings, studies in humans have confirmed that vaccine mRNA can be detected in multiple tissues, including lymph nodes, the heart, the central nervous system, and blood. Finally, persistence is not just short term. In some reports, mRNA has been detected for weeks to months, and in certain cases as long as seven zero six days post vaccination. Taken together, these data highlight that biodistribution is broad and persistence is longer than initially expected, raising important questions and concerns for ongoing research and safety monitoring.

In a deceased patient, spike protein was found in the heart but not nucleocapsid protein. The autopsy revealed bronchopneumonia, Parkinson's disease, necrotic encephalitis, and myocarditis. The author suggests that the spike protein in affected tissues was likely from gene-based COVID-19 vaccines, not a SARS CoV-2 infection, as nucleocapsid protein was absent. Spike protein was found in areas with brain and heart inflammation, possibly contributing to the disease.

"Now, when these genes, packages, enter the cells, then the cells will start making this damn virus protein which is called the spike." "This is going to happen to any mRNA or gene based vaccine." "Those packages are going to cause your cells in the blood vessels to create this protein and this protein is going to be a foreign non self protein that is going to be recognised by any antibodies that you have and these antibodies are going to be there after the first injection." "If any of these vessels is clogged because of a thrombus or because it's injured, the cells that are being supplied by oxygen are going to die." "So if these tiny vessels in the brain or the heart are damaged, you are damaged for life. You will never be the same again."

Recent studies indicate the persistence of spike protein in the body long after the initial introduction. A Yale study detected it 709 days out, while a Patterson study found it 245 days out. This extended presence is unusual, as most proteins have a turnover rate of weeks, not years. This suggests either the spike protein is being continuously regenerated within the body or it is somehow evading destruction for extended periods in bodily reservoirs. This leads to speculation that the mRNA may be lasting longer than expected or that plasmids are still present and generating spike protein. The exact mechanism behind this phenomenon is currently unknown.

Speaker 0 lays out a numerical comparison between vaccine versus infection to determine which creates more spike proteins, according to the source material. First, the infection scenario. The unit counted is the virion (one complete virus particle). At the peak of infection, the body could be fighting off somewhere between one to 100,000,000,000 virions. Each virion has spike proteins on its surface, counted as between twenty five and fifty spikes per virion. The calculation multiplies the range of virions by the spikes per virion, giving a peak infection spike protein load of two to 10,000,000,000,000 spike proteins. Next, the vaccination scenario. The math starts with modified messenger RNA (modRNA) molecules in a vaccine dose. A single vaccine dose contains somewhere between 14 to 42,000,000,000,000 modRNA molecules. Each of these trillions of modRNA molecules can produce multiple spike proteins, ranging from 10 to 1,000 each. When the numbers are multiplied, the source calculates a potential total of up to 100,000,000,000,000,000 spike proteins (up to 10^17, i.e., up to one hundred quadrillion). Speaker 0 then contrasts the two scenarios. In a side-by-side view, the initial particles are billions of virions versus trillions of modRNA molecules. The timing differs as well: a natural infection builds up over about a week, whereas the vaccine dose is delivered all at once, in just a few seconds. The final totals are two to 10,000,000,000,000 spikes from infection versus a potential of up to one hundred quadrillion from vaccination. Visually, this difference is stark, with the infection spike protein bar being far smaller than the vaccine spike protein bar, illustrating an order-of-magnitude difference. The discussion then moves to the distribution and persistence of spike proteins. The source describes the virus's spread as more localized or comparatively narrow, while vaccine components are said to travel throughout the entire body, with accumulation in areas including major organs like the heart and the brain, and the potential to cross barriers such as the blood-brain barrier and the placental barrier. Regarding duration, spike mRNA was reportedly detected in cerebral arteries after seventeen months, and some vaccinated individuals were reportedly still spike positive for up to sixteen hundred days. The source concludes, “Your spike load is orders of magnitude higher via injection.” Speaker 0 notes that the numbers show trillions versus quadrillions and emphasizes the presented math and its implications as the core of the comparison, while acknowledging the source’s look at spike proteins’ distribution and persistence.

**French Summary:** Anaïs Bloqué explique l'impact de la protéine Spike du SARS-CoV-2 sur le système immunitaire inné, en se concentrant sur le TLR 4. La Spike seule n'active pas complètement le TLR 4 pour induire une réponse antivirale complète (interférons de type 1). L'association Spike-LPS (lipopolysaccharide bactérien) est nécessaire. L'activation des interférons 1 augmente l'expression d'ACE2, récepteur du virus, via les ISG, sensibilisant l'organisme à l'infection. Les ARN messagers des vaccins peuvent aussi activer les interférons 1 via MDA5. La Spike, protéine amyloïde, peut induire la production de fibres A bêta 42, aggravant l'inflammation. L'augmentation de NF-κB par les ISG peut bloquer p53 (suppresseur de tumeur) et induire le micro-ARN MIR-200c, diminuant l'expression d'ACE2. Chez les personnes avec comorbidités (diabète, obésité), une boucle d'amplification inflammatoire Spike-LPS-TLR4 réduit l'ACE2 disponible, menant à une suractivation de l'angiotensine 2. La Spike persistante pourrait causer des pathologies dégénératives à long terme. **English Translation:** Anaïs Bloqué explains the impact of the SARS-CoV-2 Spike protein on the innate immune system, focusing on TLR 4. Spike alone does not fully activate TLR 4 to induce a complete antiviral response (type 1 interferons). The Spike-LPS (bacterial lipopolysaccharide) association is necessary. Activation of interferon 1 increases ACE2 expression, the virus receptor, via ISGs, sensitizing the body to infection. Vaccine mRNAs can also activate interferon 1 via MDA5. Spike, an amyloid protein, can induce the production of A beta 42 fibers, worsening inflammation. Increased NF-κB by ISGs can block p53 (tumor suppressor) and induce microRNA MIR-200c, decreasing ACE2 expression. In people with comorbidities (diabetes, obesity), a Spike-LPS-TLR4 inflammatory amplification loop reduces available ACE2, leading to overactivation of angiotensin 2. Persistent Spike could cause long-term degenerative pathologies.

The spike protein, according to research in South Africa, induces fibrin from fibrinogen, forming the backbone of clotting in a way not previously seen. Unlike normal fibrin clots that are easily broken down, clots formed from COVID or the spike protein from the vaccine are difficult to break down, causing issues for many people. A cardiologist stated that in their decades of practice, they have never treated as many blood clots as in the last five years. These blood clots occur after the virus infection and the vaccine because the spike protein causes blood clots. Therefore, it is reckless to continue vaccinating people and loading the body with spike protein, causing more blood clots. According to a paper in Cell (July 2021), the nucleoprotein, not the spike protein, supplied broad and durable immunity for the prevention of infection. The speaker questions why the vaccine wasn't changed to target the nucleoprotein once this information came to light.

The speaker states: "We found circulating Pfizer mRNA in his exosomes three point six years after his last shot, and we also found plasmid DNA from the manufacturing process SV40 ORI segments, as well as the spike expression segments in his skin, in his Grover's disease area. He developed this skin disease after the shots." They add: "We also found vaccine spike protein and no nucleocapsid in this skin area as well." The speaker emphasizes timing: "Three point six years after his last shot, he suffered from myocarditis, pulmonary embolism, multisystem vaccination syndrome, neurological adverse events as well." They conclude: "And so the fact that we are finding this material forty three months after the last shot means we were lied to completely." The speaker claims: "We were told it would stay in the arm, it would degrade within weeks, that was wrong and we expect lawsuits to begin to flood in."

The mRNA COVID-19 vaccine delivers instructions for creating spike proteins, which then trigger an immune response. The vaccine components are said to break down and disappear from the body within days, leaving no trace and unable to affect DNA. However, some claim that data from the Therapeutic Goods Administration in Australia shows the vaccine distributes throughout the body, not just the injection site, and that there was no data on how quickly it degrades. Research indicates vaccine mRNA can be detected in some individuals for up to 14-15 days. A rare post-vaccination syndrome (PVS) is described where individuals exhibit elevated levels of spike protein for extended periods, up to 709 days, along with reactivation of dormant viruses. A hypothesis suggests that in some individuals, the vaccine mRNA may reverse transcribe and integrate into DNA, causing continuous spike protein production and potentially leading to T-cell exhaustion. The concern is raised about the long-term health consequences and potential for germline transfer if DNA is altered.

Speaker 0 describes what he claims is the strongest case report ever done on vaccine injury, specifically mRNA vaccine injury. The subject is a 51-year-old man who developed myocarditis, pulmonary embolism, neurological disturbances, and skin disturbances, constituting multisystem long vaccine syndrome. The key findings are said to be detected 3.6 years after his last shot. Exosomes circulating in his body allegedly contain Pfizer mRNA, and this mRNA is still present in those exosomes years after vaccination. The same mRNA is reportedly also found in his skin. In addition, plasmid DNA from the manufacturing process is claimed to be present in his skin, again 3.6 years after vaccination. Specifically, the plasmid DNA allegedly includes the SV40 segment, the spike expression cassette, and the open reading frame region, with all components of the plasmids in the Grover's disease–affected skin area. Microscopic analysis of the Grover’s disease area allegedly showed staining for SARS-CoV-2 spike or vaccine spike, indicating the presence of spike protein in that skin region. This staining for spike protein is reported as occurring 3.6 years after the shot. Overall, the speaker asserts that all vaccine components—mRNA, plasmid DNA with defined segments, and spike protein—remain in the body for multiple years, with findings in exosomes and skin indicating long-lasting presence. The speaker also asserts that this represents a situation in which “we were completely lied to.”

Many people have received the COVID-19 vaccines, but there may be long-term impacts. However, 25% of people have not received the vaccine. We are currently dealing with shedding and the mRNA. To protect themselves, people should follow a daily protocol. A major paper called "Base Spike Detox" will soon be published, which suggests using three natural products: nattokinase, bromelain, and curcumin. These products can help with the spike protein loaded into the body. It is recommended to take this triple combination for at least three months, but some may need it for up to 9 or 12 months. It is important to be aware of potential side effects and consult with doctors. Action needs to be taken now, as more studies will come later.

Residual effects from one or two COVID shots can include late blood clots and cardiac arrests years later. The mRNA and spike protein from the shots can linger in the body, causing various health issues like heart and brain damage, blood clots, and immunologic problems. A spike detox program is recommended to address these concerns.

Lipid nanoparticles, not intended for human or veterinary use, were administered to billions of people worldwide. Synthetic RNA from the vaccines persisted for months in the body. The spike protein, found in the brain, peripheral nerves, and organs, caused damage and autoimmune diseases. Spike protein accumulation was also observed in the heart, renal glands, and elastic fibers of the skin. Reproductive harms, such as placental and testicular damage, were reported. The spike protein affected the body's ability to react to other infections and weakened the immune system. It caused damage to blood vessels, including small and large vessels, and led to coronary events and abnormal protein accumulation. The immune system was blinded, leading to a decrease in tumor surveillance and tolerance to pathogens. The video also mentioned the potential impact on cancer.

Yale researchers discovered COVID spike proteins in the blood of individuals who received mRNA vaccines, even up to two years post-vaccination, without prior COVID infection. This raises concerns that the vaccine's genetic material may have integrated with human DNA, leading to ongoing spike protein production. While the findings suggest potential long-term effects, they do not definitively prove genetic integration. The researchers plan to publish their findings on a preprint server and seek validation from an independent lab. These developments could have significant implications for mRNA vaccine safety guidelines affecting over a billion vaccinated individuals. Further details will be shared as the research progresses.

The mRNA COVID-19 vaccine delivers instructions for creating spike proteins, which then triggers an immune response. The vaccine and spike protein are said to break down and disappear within days, leaving no trace and not affecting DNA. The vaccine is taken up at the injection site and quickly metabolized. However, an Australian Therapeutic Goods Administration document indicates the vaccine distributes throughout the body, including adipose tissue, adrenal glands, and the brain. There was allegedly no data on how quickly the mRNA degrades. Research indicates vaccine mRNA can be detected up to 14-15 days post-vaccination in some individuals. A rare post-vaccination syndrome (PVS) is associated with chronic conditions and elevated spike protein levels up to 709 days post-vaccination, even without detectable SARS-CoV-2 infection. One hypothesis suggests that the mRNA may reverse transcribe and integrate into DNA, causing continuous spike protein production and potentially leading to T cell exhaustion. The possibility of germline transfer and long-term health consequences is raised.

Bonjour à tous, Anaïs Bloqué, docteur en biologie santé, explique les impacts de la protéine Spike du SARS-CoV-2 sur le système immunitaire inné, basés sur son article récent. La Spike seule n'active pas complètement le TLR 4, un récepteur immunitaire, et ne produit pas d'interférons de type 1, essentiels pour la réponse antivirale. Pour une activation complète, la Spike doit s'associer au LPS (des bactéries Gram négatif). L'activation des interférons 1 augmente l'expression d'ACE2, le récepteur du virus, via les ISG, sensibilisant l'organisme à l'infection. Les ARN messagers des vaccins peuvent aussi lancer la production d'interférons 1 via MDA5. La Spike, protéine amyloïde, peut aussi déclencher le TLR 4 avec des fibres amyloïdes, entraînant un "double effet amyloïde". L'augmentation de NF-κB par les ISG peut bloquer la p53, potentiellement cancérigène. De plus, NF-κB induit le MIR-200c, qui bloque l'ACE2. Chez les individus avec comorbidités, une boucle d'amplification inflammatoire se crée : Spike-LPS-TLR4 induit interférons 1, ISG, surexpression d'ACE2, augmentation de NF-κB, MIR-200c, diminution d'ACE2 et augmentation d'angiotensine 2. La Spike persiste longtemps, et ses propriétés amyloïdes font craindre des pathologies dégénératives à long terme. --- Hello everyone, Anaïs Bloqué, PhD in health biology, explains the impacts of the SARS-CoV-2 Spike protein on the innate immune system, based on her recent article. Spike alone does not fully activate TLR 4, an immune receptor, and does not produce type 1 interferons, which are essential for the antiviral response. For complete activation, Spike must associate with LPS (from Gram-negative bacteria). Activation of interferon 1 increases the expression of ACE2, the virus's receptor, via ISGs, sensitizing the body to infection. Vaccine mRNAs can also trigger the production of interferon 1 via MDA5. Spike, an amyloid protein, can also trigger TLR 4 with amyloid fibers, leading to a "double amyloid effect." The increase in NF-κB by ISGs can block p53, which is potentially carcinogenic. In addition, NF-κB induces MIR-200c, which blocks ACE2. In individuals with comorbidities, an inflammatory amplification loop is created: Spike-LPS-TLR4 induces interferon 1, ISG, ACE2 overexpression, increased NF-κB, MIR-200c, decreased ACE2 and increased angiotensin 2. Spike persists for a long time, and its amyloid properties raise concerns about long-term degenerative pathologies.

About 15% of people who have taken the vaccines are experiencing medical problems, including late development of myocarditis and cardiac arrests, as well as blood clots even 2 years after vaccination. However, around a third of people who took the vaccine have had no side effects. A detoxification protocol has been published in the US medical literature, which suggests using three natural substances to help clear the dangerous protein from the body: nattokinase, bromelain, and curcumin. The recommended doses are provided. The duration of the protocol is at least 3 months, or longer for those who have received multiple shots. Although there are no confirmed trials, the speaker's clinical observation suggests that patients are improving.

Lipid nanoparticles, not intended for human or veterinary use, were administered to billions of people worldwide. Synthetic RNA and spike proteins from the vaccines were found to persist in the body for months, accumulating in the brain, peripheral nerves, liver, and other organs. Autoimmune diseases, myocarditis, renal gland damage, and reproductive harms were also observed. The spike protein affected the immune system, weakened the body's response to other infections, and caused damage to blood vessels, including the coronary vessels. It also led to the accumulation of abnormal proteins in the blood and impaired tumor surveillance. The potential impact on cancer was highlighted as a significant concern.